ホーム>>Signaling Pathways>> Neuroscience>> mAChR>>Arecoline hydrobromide

Arecoline hydrobromide

カタログ番号GC10264

ムスカリン性アセチルコリン受容体作動薬

Products are for research use only. Not for human use. We do not sell to patients.

Arecoline hydrobromide 化学構造

Cas No.: 300-08-3

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$38.00
在庫あり
50mg
$50.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Arecoline hydrobromide is a nicotinic acids-based alkaloid and partial agonist of muscarinic acetylchiline M1, M2, M3 and M4 receptors. The LD50 of subcutaneous injection value is 100 mg/kg in mouse [1].

Arecoline hydrobromide has been suggested to have electrophysiological effects on ventricular myocytes. Arecoline hydrobromide has shown the significant inhibitory effect on hERG current with the IC50 value of 9.55μmol/L. Furthermore, Arecoline hydrobromide has demonstrated the concentration- , time- and voltage-dependent characteristics of IhERG inhibition in the patch clamp experiments. Apart from these, Arecoline hydrobromide has been exhibited to significant change in the amount of steady-state blockade at stimulation frequencies. It has been shown frequency-dependent characteristics inhibition of IhERG by Arecoline hydrobromide [1].

References:
[1] Zhao XY1, Liu YQ, Fu YC, Xu B, Gao JL, Zheng XQ, Lin M, Chen MY, Li Y. Frequency- and state-dependent blockade of human ether-a-go-go-related gene K+ channel by arecoline hydrobromide. Chin Med J (Engl). 2012 Mar;125(6):1068-75.

レビュー

Review for Arecoline hydrobromide

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Arecoline hydrobromide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.